Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $1.1 million.

  • Agios Pharmaceuticals' Capital Expenditures rose 1582.21% to $1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year increase of 15614.24%. This contributed to the annual value of $4.3 million for FY2025, which is 15614.24% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Capital Expenditures of $1.1 million as of Q4 2025, which was up 1582.21% from $1.6 million recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year Capital Expenditures high stood at $4.5 million for Q4 2021, and its period low was -$22000.0 during Q3 2021.
  • For the 5-year period, Agios Pharmaceuticals' Capital Expenditures averaged around $881100.0, with its median value being $409000.0 (2023).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Capital Expenditures tumbled by 10042.28% in 2021, and later surged by 536666.67% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Capital Expenditures (Quarter) stood at $4.5 million in 2021, then plummeted by 97.49% to $113000.0 in 2022, then skyrocketed by 107.08% to $234000.0 in 2023, then surged by 313.25% to $967000.0 in 2024, then rose by 15.82% to $1.1 million in 2025.
  • Its Capital Expenditures stands at $1.1 million for Q4 2025, versus $1.6 million for Q3 2025 and $875000.0 for Q2 2025.